Glenmark Pharmaceuticals Ltd

GLENMARK

₹1,791.56

₹0.32

0.02%

Healthcare

₹0.00

(%)1D

Updated: 07 Nov 2025, 03:31:00 pm IST

Stock Score

Open Price

₹1,781.27

Prev. Close

₹1,791.24

₹1,781.27

Day Low

₹1,809.61

Day High

₹1,261.12

52 Week Low

₹2,255.66

52 Week High

Quick Bite

Price To Earnings Ratio 67.07	Sector PE 10.73
PB Ratio 5.72	Sector PB 5.84
EPS 26.71	Dividend Yield 0.16
Today's Volume 552.052 K	5 Day Avg. Volume 507.005 K
PEG Ratio 0.40	Market Cap. ₹ 53,370.00 Cr.

News & Events

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company's offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

Glenmark Pharmaceuticals Ltd Share Price

Glenmark Pharmaceuticals Ltd has a significant presence in the branded generics market in all emerging economies including India. The company entered the dermatology market with the launch of Candid cream. Glenmark's pioneering drug development focuses primarily on inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. The company's formulation business focuses on therapeutic areas, e.g. dermatology, infectious medicine, respiratory, cardiac, diabetes, gynecology, central nervous system and oncology. India is the organization's largest market region by revenue.

Glenmark Pharmaceuticals Ltd FAQs

How to Buy Glenmark Pharmaceuticals Ltd Share?

To purchase Glenmark Pharmaceuticals Ltd shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Glenmark Pharmaceuticals Ltd (ticker symbol: GLENMARK) on the trading platform provided by your broker and purchase the shares.

What's Glenmark Pharmaceuticals Ltd share price today?

The stock price of Glenmark Pharmaceuticals Ltd as of 09 Nov 2025 is ₹1,791.56

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Market capitalisation represents the total market value of a company's outstanding shares. As of 09 Nov 2025, Glenmark Pharmaceuticals Ltd (ticker symbol: GLENMARK) has a market capitalisation of approximately ₹5,33,70,00,00,000.00

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd Ltd's price-to-book ratio as of 09 Nov 2025 is 5.72, reflecting the market's valuation compared to its asset value. As of 09 Nov 2025, the trailing twelve months P/E (price-to-earnings) ratio is 67.07, indicating the market values the company at around ₹67.07 for every ₹1 of earnings

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd Share?

Glenmark Pharmaceuticals Ltd Ltd (GLENMARK) hit its 52-week high at ₹2,255.66, and its 52-week low at ₹1,261.12.

Begin your investment journey today

View All Global Indices